Guggenheim raised the firm’s price target on Eli Lilly to $1,030 from $884 and keeps a Buy rating on the shares. The guidance increase again reflects Eli Lilly’s overall business momentum keyed to rapidly expanding incretin supply and unprecedented obesity market demand, the analyst tells investors in a research note. The guidance highlights accelerating profitability and the firm’s review of Lilly’s rapidly advancing pipeline increases its confidence in sustained business momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Roche passed on weight-loss pilll now being developed by Eli Lilly, FT says
- U.S. to announce prices for drugs in Medicare negotiations, NY Times says
- LLY, NVO: Which GLP-1 Stock Is the Better Bet?
- Tiger Global buys Qualcomm, exits Instacart in Q2
- Eli Lilly price target raised to $1,050 from $1,000 at Berenberg